RapidAI, a San Mateo, Calif.-based leader in advanced imaging for stroke, raised $25m in Series B funding.
The round was by Lennertz & Co. Building.
The company intends to use the funds to advance the Rapid® platform and its clinical products.
Founded in 2011 and led by Don Listwin, CEO, RapidAI makes cerebrovascular imaging products for patient care, research, and clinical trials. It offers an end-to-end portfolio of advanced stroke imaging and stroke assessment products for hospitals of all sizes. The platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans, helping hospitals to speed up time-critical triage or transfer decisions and facilitate better patient outcomes.
The Rapid imaging platform includes Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, and Rapid MRI. RapidAI also offers SurgicalPreview®, a comprehensive aneurysm management platform.